Acadia Pharmaceuticals Inc.
Income Statement
| Line Item | FY2009 |
|---|---|
| Revenue | $6.4M |
| NUPLAZID | — |
| DAYBUE | — |
| Cost of Revenue | — |
| Gross Profit | — |
| Gross Margin | — |
| Operating Expenses | |
| Research & Development | $41.6M |
| SG&A Expense | $10.3M |
| Operating Income | $-45.5M |
| Operating Margin | -710.5% |
| Interest Expense | — |
| Pretax Income | — |
| Income Tax Expense | — |
| Net Income | $-45.1M |
| Net Margin | -705.5% |
| EPS (Basic) | $0.00 |
| EPS (Diluted) | $0.00 |
| Shares Outstanding (Basic) | 37.74B |
| Shares Outstanding (Diluted) | 37.74B |
| Dividends Per Share | — |